Form 4: NewAmsterdam Pharma CFO Mayur Ian Somaiya Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Mayur Ian Somaiya, CFO of NewAmsterdam Pharma Co N.V., exercised options and sold ordinary shares under a pre-arranged trading plan.
Summary
- On January 27 and 28, 2025, Mayur Ian Somaiya, the CFO of NewAmsterdam Pharma Co N.V., engaged in transactions involving the company's ordinary shares.
- Somaiya exercised options to acquire 46,983 shares on January 27 and 14,900 shares on January 28, both at an exercise price of $9.26.
- Concurrently, Somaiya sold shares on the open market at prices ranging from $20.93 to $23.75 per share.
- The sales were executed under a pre-arranged trading plan compliant with Rule 10b5-1 of the Securities Exchange Act of 1934.
- After these transactions, Somaiya directly owns 38,000 ordinary shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports routine transactions under a pre-arranged trading plan. There's no indication of positive or negative implications for the company's performance.
Industry Context
Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. The use of a 10b5-1 plan suggests the sales were pre-planned and intended to avoid any concerns about trading on inside information.
Key Dates
| Date | Description |
|---|---|
| 11/01/2023 | Date the option was granted. |
| 01/27/2025 | Date of option exercise and share sales. |
| 01/28/2025 | Date of option exercise and share sales. |
| 01/29/2025 | Date of signature on the Form 4 filing. |
| 11/01/2033 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.